In the past 12‑18 months, Open Angle Glaucoma Drugs industry trends have accelerated through a series of strategic moves. In March 2024, Novartis entered a co‑development partnership with Alcon to combine Novartis’ ROCK‑inhibitor pipeline with Alcon’s sustained‑release delivery platform, aiming for a once‑monthly injectable. The same period saw Allergan acquire EyeTech Therapeutics for $420 million, expanding its portfolio with a gene‑editing candidate targeting MYOC mutations. Product launches include Bausch + Lomb’s FDA‑approved micro‑implant, GlaucoFlex, which delivers low‑dose latanoprost over six months, and Santen’s first‑in‑class topical nanoparticle formulation, NanoGlaucoma, approved in the EU in September 2023. Regulatory shifts were highlighted by the FDA’s updated guidance on combination therapy endpoints, prompting sponsors to redesign Phase III trials. Meanwhile, venture capital funding surged, with MediVision closing a $150 million Series C round to scale its AI‑driven adherence platform, reflecting a broader shift toward digital monitoring in glaucoma care. Patient demand for minimally invasive procedures has risen 15 % YoY, driving manufacturers to prioritize micro‑implant and laser‑based solutions. In early 2024, Aerie Pharmaceuticals inaugurated a new GMP facility in Singapore, positioning the region as a hub for ocular drug manufacturing.
